GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » Cyclically Adjusted PB Ratio

Genmab AS (CHIX:GMABC) Cyclically Adjusted PB Ratio : 4.98 (As of Jun. 03, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Genmab AS Cyclically Adjusted PB Ratio?

As of today (2025-06-03), Genmab AS's current share price is kr1422.50. Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr285.40. Genmab AS's Cyclically Adjusted PB Ratio for today is 4.98.

The historical rank and industry rank for Genmab AS's Cyclically Adjusted PB Ratio or its related term are showing as below:

CHIX:GMABc' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.4   Med: 23.09   Max: 39.38
Current: 5.11

During the past years, Genmab AS's highest Cyclically Adjusted PB Ratio was 39.38. The lowest was 4.40. And the median was 23.09.

CHIX:GMABc's Cyclically Adjusted PB Ratio is ranked worse than
80.51% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs CHIX:GMABc: 5.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab AS's adjusted book value per share data for the three months ended in Mar. 2025 was kr576.839. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr285.40 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Genmab AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Cyclically Adjusted PB Ratio Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.30 22.49 17.79 10.22 5.69

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.25 7.37 6.50 5.69 4.81

Competitive Comparison of Genmab AS's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.


;
;

Genmab AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genmab AS's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1422.50/285.40
=4.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=576.839/120.2000*120.2000
=576.839

Current CPI (Mar. 2025) = 120.2000.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201506 47.126 100.300 56.476
201509 51.349 100.200 61.598
201512 58.794 99.800 70.812
201603 60.093 100.200 72.088
201606 62.022 100.600 74.106
201609 65.352 100.200 78.396
201612 79.944 100.300 95.805
201703 82.491 101.200 97.978
201706 90.784 101.200 107.828
201709 88.502 101.800 104.498
201712 104.053 101.300 123.467
201803 106.472 101.700 125.840
201806 110.815 102.300 130.205
201809 114.862 102.400 134.828
201812 131.293 102.100 154.568
201903 131.206 102.900 153.265
201906 135.672 102.900 158.482
201909 191.279 102.900 223.438
201912 218.131 102.900 254.804
202003 221.135 103.300 257.313
202006 273.865 103.200 318.978
202009 281.591 103.500 327.026
202012 295.459 103.400 343.464
202103 302.680 104.300 348.822
202106 304.858 105.000 348.990
202109 321.000 105.800 364.690
202112 338.376 106.600 381.546
202203 350.217 109.900 383.040
202206 368.046 113.600 389.429
202209 402.326 116.400 415.460
202212 421.840 115.900 437.491
202303 424.249 117.300 434.738
202306 441.697 116.400 456.117
202309 471.413 117.400 482.656
202312 491.001 116.700 505.727
202403 495.032 118.400 502.558
202406 485.686 118.500 492.654
202409 505.732 118.900 511.261
202412 573.875 118.900 580.149
202503 576.839 120.200 576.839

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab AS  (CHIX:GMABc) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genmab AS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines